Frontline therapy with ibrutinib and venetoclax demonstrates a manageable safety profile and produces high overall response rates in older patients with #MCL
According to Blood, this strategy yields high complete response rates and durable remission rates!
Read more here: https://bit.ly/4jefhwu
